These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 17403121

  • 1. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes.
    Home PD, Bailey CJ, Donaldson J, Chen H, Stewart MW.
    Diabet Med; 2007 Jun; 24(6):618-25. PubMed ID: 17403121
    [Abstract] [Full Text] [Related]

  • 2. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
    Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M.
    Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):6-13. PubMed ID: 18095238
    [Abstract] [Full Text] [Related]

  • 3. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.
    Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW.
    Clin Ther; 2005 Oct; 27(10):1548-61. PubMed ID: 16330291
    [Abstract] [Full Text] [Related]

  • 4. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [Abstract] [Full Text] [Related]

  • 5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Nov; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 6. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V, Rosenstock J, Patwardhan R, Salzman A.
    JAMA; 2000 Apr 05; 283(13):1695-702. PubMed ID: 10755495
    [Abstract] [Full Text] [Related]

  • 7. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL, Stewart J, Issa M, Lake B, Melis R.
    Clin Ther; 2005 Oct 05; 27(10):1535-47. PubMed ID: 16330290
    [Abstract] [Full Text] [Related]

  • 8. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.
    Diabetes Care; 2006 Mar 05; 29(3):554-9. PubMed ID: 16505505
    [Abstract] [Full Text] [Related]

  • 9. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH, Charbonnel B, Li J, Donovan M, Fleming D, Iqbal N.
    Clin Drug Investig; 2013 Oct 05; 33(10):707-17. PubMed ID: 23949898
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
    Scott R, Loeys T, Davies MJ, Engel SS, Sitagliptin Study 801 Group.
    Diabetes Obes Metab; 2008 Sep 05; 10(10):959-69. PubMed ID: 18201203
    [Abstract] [Full Text] [Related]

  • 11. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 May 05; 14(5):409-18. PubMed ID: 22059736
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
    Owens DR, Swallow R, Dugi KA, Woerle HJ.
    Diabet Med; 2011 Nov 05; 28(11):1352-61. PubMed ID: 21781152
    [Abstract] [Full Text] [Related]

  • 13. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.
    Clin Ther; 2007 Nov 05; 29(11):2349-64. PubMed ID: 18158076
    [Abstract] [Full Text] [Related]

  • 14. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Garber A, Klein E, Bruce S, Sankoh S, Mohideen P.
    Diabetes Obes Metab; 2006 Mar 05; 8(2):156-63. PubMed ID: 16448519
    [Abstract] [Full Text] [Related]

  • 15. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.
    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.
    Clin Ther; 2007 Sep 05; 29(9):1900-14. PubMed ID: 18035190
    [Abstract] [Full Text] [Related]

  • 16. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
    Bosi E, Dotta F, Jia Y, Goodman M.
    Diabetes Obes Metab; 2009 May 05; 11(5):506-15. PubMed ID: 19320662
    [Abstract] [Full Text] [Related]

  • 17. Rosiglitazone RECORD study: glucose control outcomes at 18 months.
    Home PD, Jones NP, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Komajda M, Curtis P, RECORD Study Group.
    Diabet Med; 2007 Jun 05; 24(6):626-34. PubMed ID: 17517066
    [Abstract] [Full Text] [Related]

  • 18. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.
    Rosenstock J, Rood J, Cobitz A, Huang C, Garber A.
    Diabetes Obes Metab; 2006 Nov 05; 8(6):643-9. PubMed ID: 17026488
    [Abstract] [Full Text] [Related]

  • 19. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
    Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O, Parving HH, Vaag AA.
    BMJ; 2009 Nov 09; 339():b4324. PubMed ID: 19900993
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
    Arechavaleta R, Seck T, Chen Y, Krobot KJ, O'Neill EA, Duran L, Kaufman KD, Williams-Herman D, Goldstein BJ.
    Diabetes Obes Metab; 2011 Feb 09; 13(2):160-8. PubMed ID: 21199268
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.